caa a22 4500 60624140X CHVBK 20210128101312.0 cr unu---uuuuu 210128e20150501xx s 000 0 eng 10.1007/s00508-014-0668-4 doi (NATIONALLICENCE)springer-10.1007/s00508-014-0668-4 Patient's behavior and attitudes toward the management of benign prostatic hyperplasia among patients with the risk of disease progression: prospective study by "Prostate and Expectations of Treatment Epidemiology Research (PETER) study group” [Elektronische Daten] [Peter Weibl, Tobias Klatte, Peter Laurinc, Roman Tomaškin, Shahrokh F. Shariat, Miroslav Helbich, Danica Fackovcova, Peter Bujdák] Miktionsbeschwerden und Therapieerwartungen von Patienten mit benigner Prostatahyperplasie unter medikamentöser Therapie mit Risiko einer klinischen Progression: eine prospektive Studie der "Prostate and Expectations of Treatment Epidemiology Research" (PETER) Gruppe Summary: Background: The aim of the study was to evaluate patients attitudes with benign prostatic hyperplasia at the risk of progression during a 12-month period of observation. Materials and methods: A total of 426 patients from 45 outpatients centers were included and prospectively followed. Inclusion criteria were: age >50 years, International Prostate Symptom Score (IPSS) >8, prostate volume >30cm3 (transabdominal ultrasound) and PSA >1.5 to <10ng/ml. Results: In all, 28.6% patients were naive, 62.9% used monotherapy (alpha-blocker), and 8.5% combined treatment (alpha-blocker/5alpha-reductase inhibitor/dutasteride). The most bothersome symptoms were the weak urine stream (60.8%) and nocturia (59.2%). Patients expectations from the treatment were stabilization of the disease and reducing the risk of surgery rather than rapid resolution of symptoms. Despite the presence of symptoms, 2.3% patients claimed that benign prostatic hyperplasia/lower urinary tract symptoms had no impact on their quality of life (QoL), in 48.1% only little impact on QoL, and 47.9% patients percepted their symptoms as severe. Out of 71.4% patients treated previously, 26.5% patients were indecisive about the satisfaction of present treatment. Visual analog score was percepted more optimistically rather than the IPSS. Pearsonʼs correlation r=0.68 at the beginning and r=0.83 at the end of the study. Conclusions: Prostate and Expectations of Treatment Epidemiology Research study highlights and reflects on patients behavior and self-perception, patients self-perception of the disease and therapeutic priorities during the 1 year of observation. Springer-Verlag Wien, 2014 Benign prostatic hyperplasia nationallicence Lower urinary tract symptoms nationallicence Patientʼs behavior nationallicence Benigne Prostatahyperplasie nationallicence Miktionsbeschwerden nationallicence Patient nationallicence Einstellung nationallicence Wahrnehmung nationallicence Weibl Peter Department of Urology, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria aut Klatte Tobias Department of Urology, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria aut Laurinc Peter Department of Urology, University Hospital, Žilina, Slovakia aut Tomaškin Roman Department of Urology, Medical University, Martin, Slovakia aut Shariat Shahrokh F. Department of Urology, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria aut Helbich Miroslav Caldera, Bratislava, Slovakia aut Fackovcova Danica GlaxoSmithKline, Bratislava, Slovakia aut Bujdák Peter Department of Urology, Slovak Medical University, Bratislava, Slovakia aut Wiener klinische Wochenschrift Springer Vienna 127/9-10(2015-05-01), 363-368 0043-5325 127:9-10<363 2015 127 508 https://doi.org/10.1007/s00508-014-0668-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00508-014-0668-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Weibl Peter Department of Urology, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria aut NATIONALLICENCE 700 1- Klatte Tobias Department of Urology, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria aut NATIONALLICENCE 700 1- Laurinc Peter Department of Urology, University Hospital, Žilina, Slovakia aut NATIONALLICENCE 700 1- Tomaškin Roman Department of Urology, Medical University, Martin, Slovakia aut NATIONALLICENCE 700 1- Shariat Shahrokh F. Department of Urology, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria aut NATIONALLICENCE 700 1- Helbich Miroslav Caldera, Bratislava, Slovakia aut NATIONALLICENCE 700 1- Fackovcova Danica GlaxoSmithKline, Bratislava, Slovakia aut NATIONALLICENCE 700 1- Bujdák Peter Department of Urology, Slovak Medical University, Bratislava, Slovakia aut NATIONALLICENCE 773 0- Wiener klinische Wochenschrift Springer Vienna 127/9-10(2015-05-01), 363-368 0043-5325 127:9-10<363 2015 127 508